This product is a combination of two distinct peptides that act on the growth-hormone axis through different mechanisms: Tesamorelin, a synthetic analogue of growth-hormone-releasing hormone (GHRH), and Ipamorelin, a selective growth-hormone secretagogue that activates the ghrelin (GHS-R) receptor. It is not a single molecule and has no single chemical formula. Each component has its own published literature; the blend itself has not been the subject of dedicated peer-reviewed study. Supplied for laboratory research use only (RUO).
Sequence & identity
Blend of two peptides: Tesamorelin (a 44-amino-acid GHRH(1–44) analogue with an N-terminal trans-3-hexenoyl modification) and Ipamorelin (the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2). No combined formula is defined.
This is a multi-peptide blend, not a single compound. The two peptides differ greatly in size (Tesamorelin ≈ 5136 g/mol; Ipamorelin ≈ 712 g/mol) and structure. Any structural depiction refers to one component only.
Mechanisms studied
Tesamorelin (GHRH analogue). Tesamorelin is a synthetic analogue of human GHRH(1–44). An N-terminal trans-3-hexenoic acid group was added to slow degradation by dipeptidyl peptidase-4 (DPP-4). Studies report that it binds and activates the GHRH receptor on the anterior pituitary, and clinical trials observed increased circulating IGF-1, consistent with stimulation of endogenous growth-hormone release 13.
Ipamorelin (GHRP / GHS-R agonist). Ipamorelin is a pentapeptide that researchers characterised as an agonist of the growth-hormone secretagogue receptor (GHS-R), the same receptor targeted by ghrelin. In rats and swine it stimulated growth-hormone release with potency comparable to GHRP-6, but — distinctively — it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses more than 200-fold above the GH ED502.
The two peptides act on separate but converging pathways (GHRH receptor versus ghrelin receptor). No published study has characterised the pharmacology of the two administered together as a fixed blend.
Dosing in the research literature
The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.
| Source / model | Regimen reported | Notes |
|---|---|---|
| Falutz et al. 2010 / Phase III lipodystrophy trials (Tesamorelin component) | 2 mg subcutaneous once daily (clinical-trial parameter for tesamorelin alone) | Reported in human trials of tesamorelin as a single agent for HIV-associated lipodystrophy. This is a component study parameter, NOT a direction for the blend or for human use of this RUO product. |
| Raun et al. 1998, Eur J Endocrinol (Ipamorelin component) | Animal-model dose-response (rats, swine); no established human regimen | Ipamorelin characterisation was conducted in animals. No standard human dosing is established. Listed only as a component research parameter, not a blend direction. |
Effects observed in research
Reported for Tesamorelin (component). In two Phase III randomised controlled trials in HIV-associated lipodystrophy (n ≈ 412 and n ≈ 404), researchers observed a statistically significant reduction in visceral adipose tissue (a net reduction of roughly 15% versus placebo over 26 weeks), increases in IGF-1 (approximately +106 to +109 ng/mL), and reductions in triglycerides in pooled analysis. Effects on visceral fat reversed after discontinuation. An FDA review noted a higher incidence of new-onset diabetes mellitus in the tesamorelin groups 13.
Reported for Ipamorelin (component). Preclinical studies reported selective stimulation of growth-hormone release without significant elevation of ACTH, cortisol, or prolactin 2.
For the blend specifically: no efficacy or safety outcomes have been published. The above are single-component findings and should not be read as outcomes of the combination.
Strength of evidence
Honest assessment. Tesamorelin has Grade A–B evidence as a single agent (FDA-approved, multiple human RCTs) for its approved indication; Ipamorelin rests largely on Grade C evidence (animal and in-vitro characterisation, limited human data). However, the fixed blend of the two has essentially no direct published study — there are no peer-reviewed trials of this specific combination establishing its pharmacokinetics, efficacy, or safety. The combined evidence grade is set at C to reflect that the product as sold (the blend) is not directly studied, and any rationale is extrapolated from separate component literature. Interaction effects, combined safety, and dosing for the blend are Not established.
Reconstitution & storage
Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.
References
- 1. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: Phase III randomized controlled trials. (Tesamorelin component evidence.) PubMed.
- 2. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552–561. PMID: 9849822.
- 3. Stanley TL, Grinspoon SK. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. PMC3218714. (Review of tesamorelin Phase III data.)
- 4. PubChem CID 16137828 (Tesamorelin); PubChem CID 9831659 (Ipamorelin). National Library of Medicine. Component identity and physicochemical data.